Dauntless Investment Group discloses 1.17% OKYO (OKYO) ownership stake

Rhea-AI Filing Summary

Dauntless Investment Group, LLC filed Amendment No. 3 to a Schedule 13G reporting a passive ownership position in OKYO Pharma Ltd. The firm reports beneficial ownership of 471,523 common shares, representing 1.17% of the class as of December 31, 2025.

Dauntless, a Delaware single family office/passive investor, reports no sole or shared voting power over OKYO shares. It has sole dispositive power over 360,352 shares and shared dispositive power over 111,171 shares, and certifies the holdings are not for changing or influencing control of OKYO Pharma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:19 PM Learn about SEC filing dates

FAQ

What ownership in OKYO (OKYO) does Dauntless Investment Group report?

Dauntless Investment Group reports beneficial ownership of 471,523 OKYO Pharma common shares, equal to 1.17% of the class. This is disclosed in an amended Schedule 13G as of December 31, 2025, reflecting a relatively small, minority position in the company.

Is Dauntless Investment Group a passive or active investor in OKYO (OKYO)?

Dauntless identifies itself as a single family office and passive investor in OKYO Pharma. It certifies the securities were not acquired, and are not held, for the purpose or effect of changing or influencing control of the issuer, consistent with passive Schedule 13G status.

How much voting power does Dauntless have over its OKYO (OKYO) shares?

Dauntless reports zero sole voting power and zero shared voting power over OKYO Pharma shares. While it is a beneficial owner, it does not control how the shares are voted, which further supports its characterization as a passive, non‑controlling investor in the company.

What dispositive power does Dauntless hold over OKYO (OKYO) shares?

Dauntless reports sole dispositive power over 360,352 OKYO Pharma shares and shared dispositive power over 111,171 shares. Dispositive power means the ability to sell or direct the sale of the shares, even though Dauntless has no reported voting authority over the securities.

Why does Dauntless file a Schedule 13G/A for its OKYO (OKYO) holdings?

The amended Schedule 13G is filed because Dauntless holds more than a minimal stake, but under 5% of OKYO Pharma’s common stock, as a passive investor. Schedule 13G allows certain investors to report beneficial ownership without intending to influence control of the issuer.

What is the date of the ownership information Dauntless reports for OKYO (OKYO)?

The ownership information Dauntless reports for OKYO Pharma is stated as of December 31, 2025. This date marks the event requiring the filing, providing a specific reference point for the 471,523 shares and 1.17% beneficial ownership stake disclosed in the Schedule 13G amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

OKYO Pharma Ltd

(Name of Issuer)

Common

(Title of Class of Securities)

G6724L116

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G6724L116

1

Names of Reporting Persons

Dauntless Investment Group, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 360,352.00
8	Shared Dispositive Power 111,171.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

471,523.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Single Family Office/Passive Investor

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OKYO Pharma Ltd
(b)	Address of issuer's principal executive offices: Floor 4, 14/15 Conduit St, LONDON, UNITED KINGDOM, W1S 2XJ.
Item 2.
(a)	Name of person filing: Dauntless Investment Group, LLC
(b)	Address or principal business office or, if none, residence: 3283 Foxfire Dr., Milford, MI 48380
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common
(e)	CUSIP No.: G6724L116
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 471,523
(b)	Percent of class: 1.17%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 360,352
	(iv) Shared power to dispose or to direct the disposition of: 111,171
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dauntless Investment Group, LLC

Signature:	/s/Matthew Okkerse
Name/Title:	CFO
Date:	02/12/2026